Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen Reveals Executive Transition Plans | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Amgen Reveals Executive Transition Plans

Dr. Sean E. Harper, EVP, R&D, and Anthony C. Hooper, EVP, Global Commercial Operations, are set to retire from their roles

By: Betsy Louda

, Contract Pharma

Amgen has announced transition plans for two of its executive vice presidents as part of a planned executive succession to address upcoming requirements.

After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean E. Harper, M.D., executive vice president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community. David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology at Amgen, has been appointed as executive vice president of Research and Development, effective today. Reese will report to Robert A. Bradway, chairman and chief executive officer. Harper will remain at Amgen for a period of time to facilitate the transition to Reese. 

In September 2018, Anthony C. Hooper, currently executive vice president of Global Commercial Operations, will retire from this role. Murdo Gordon, chief commercial officer of Bristol-Myers Squibb Company, has been named as executive vice president of Global Commercial Operations, effective Sept. 3, 2018. Gordon will report to Bradway. Hooper will also remain at Amgen for a period of time to facilitate the transition to Gordon.
 
“I would like to thank both Sean and Tony for the important contributions they have made to Amgen, each bringing their own vital experiences and skills,” said Bradway. “They leave the Company having established strong foundations within Research and Development and Global Commercial Operations for the future. It is a testament to their leadership and accomplishments that they have attracted such exceptional talent to succeed them.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters